Propanc Biopharma Net Income vs. Return On Asset
Propanc Biopharma Common's market price can diverge from book value, the accounting figure shown on Propanc's balance sheet. Propanc Biopharma's market capitalization is 1.9 M. A P/B ratio of 0.18 suggests Propanc Biopharma trades near or below book value. Enterprise value stands at 2.98 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
It is useful to distinguish Propanc Biopharma's value from its trading price, which are computed with different methods. For Propanc Biopharma, key inputs include a P/B ratio of 0.18, and ROE of -18.12%. The quoted Propanc Biopharma price is the exchange level where supply meets demand.
Propanc Biopharma Common Return On Asset vs. Net Income Fundamental Analysis
Cross-company financial ratios help determine Propanc Biopharma's valuation standing. Propanc Biopharma Common is rated fourth in net income among leading competitors. It also is rated fourth in return on asset among leading competitors . Net Loss is evolving in line with broader financial reporting trends. Year-ago financials show Propanc Biopharma with Net Loss of -53.03 Million. Earnings-based multiples benchmark Propanc Biopharma's market valuation.Propanc Return On Asset vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Propanc Biopharma |
| = | -58.92 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Return on Assets (ROA) measures how efficiently a company generates profit relative to its total asset base. It is calculated by dividing net income by total assets and reflects management's effectiveness at deploying capital across the business. ROA is particularly useful for comparing companies within the same industry, since asset intensity varies widely across sectors.
Propanc Biopharma |
| = | -5.36 |
A higher ROA indicates that each dollar of assets produces more income, which generally signals operational efficiency. Asset-heavy industries such as banking, utilities, and manufacturing tend to have lower ROAs than asset-light businesses like software or professional services. When ROA is low, it may indicate either underperforming operations or a capital-intensive business model that requires ongoing investment to sustain revenue.
Propanc Return On Asset Comparison
Propanc Biopharma is currently under evaluation in return on asset among leading competitors.
Propanc Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Propanc Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Propanc Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Propanc Biopharma's change in net profit over the period of time. It can combine multiple indicators of Propanc Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | End Of Year Estimate | ||
| Accumulated Other Comprehensive Income | 1.5 M | 1.6 M | |
| Operating Income | -51.6 M | -49 M | |
| Income Before Tax | -53 M | -50.4 M | |
| Total Other Income Expense Net | -1.5 M | -1.6 M | |
| Net Loss | -53 M | -50.4 M | |
| Income Tax Expense | -116.1 K | -121.9 K | |
| Net Loss | -53 M | -50.4 M | |
| Net Loss | -3.6 M | -3.8 M | |
| Net Interest Income | -648.3 K | -680.7 K | |
| Interest Income | 8.10 | 7.69 | |
| Change To Netincome | 771.2 K | 1.3 M | |
| Net Loss | -17.08 | -17.93 | |
| Income Quality | 0.01 | 0.01 | |
| Net Income Per E B T | 0.93 | 1.07 |
Propanc Profitability Driver Comparison
Understanding Propanc Biopharma's profitability drivers is essential for assessing the sustainability of its earnings. Unexpected events such as tax policy changes, commodity price shocks, or economic downturns can materially alter the profit outlook and affect long-term investment returns.
Earnings per Share Projection vs Actual
Use Propanc Biopharma in pair-trading
A pair strategy built around Propanc Biopharma Common is useful when investors want to reduce directional market exposure while still expressing a relative-value idea. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Propanc Biopharma Pair Trading
Propanc Biopharma Common Pair Trading Analysis
Correlation analysis helps investors find suitable substitutes for Propanc Biopharma during tax-loss harvesting periods. Selling Propanc Biopharma Common at a loss and immediately repurchasing it would violate IRS wash-sale rules, so a correlated replacement asset is required to maintain portfolio.
Measuring the statistical correlation of Propanc Biopharma Common against other instruments helps investors understand portfolio diversification. A correlation near zero implies that Propanc Biopharma provides genuine diversification benefits, while high positive correlations suggest redundant exposures.
Correlation analysis and pair evaluation for Propanc Biopharma can support hedging context. The method can be applied across sectors and broader equity sets.Use Investing Themes to Complement your Propanc Biopharma position
Propanc Biopharma Common Healthcare sector classification and 1.9 Million smaller-cap scale make it a natural anchor for themes targeting Biotechnology exposure. For Propanc Biopharma Common in Biotechnology, the theme workflow defines the investment thesis first, then optimizes which Healthcare assets best express that view at the smaller-cap level.
Did You Try This Idea?
Run Cleaning Thematic Idea Now
Cleaning
Compnanies producing and distributing cleaning products, supplies, and accessories. The Cleaning theme has 41 constituents at this time.
The Cleaning Theme can be deployed as a buy-and-hold allocation or traded actively around individual position volatility.
| View All Next | Launch |